We used 30 cancer cell lines with different KRAS mutations and multiple in vitro assays to show that both pharmacologic and genetic KRAS inhibition is selectively effective against KRAS-mutant murine and human tumors in vivo. The gene discussed is KRAS; the disease is cancer.